

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	V-region immunoglobulin-containing suppressor of T cell activation (VISTA)	Cell culture and mouse studies suggest inhibiting VISTA could help treat cancer. In cultured human CD4 ⁺ and CD8 ⁺ T cells, a VISTA-Ig fusion protein decreased anti-CD3 mAb-induced T cell proliferation compared with control Ig. In multiple mouse xenograft tumor models, a VISTA mAb decreased tumor growth and increased the number of effector T cells in the tumor compared with control antibody. In a mouse model of melanoma, the VISTA mAb increased T cell tumor infiltration compared with control antibody and delayed tumor progression. Next steps include testing anti-VISTA mAbs alone or in combination with other therapeutics in additional tumor models.	Findings from both studies patented; licensed to ImmNext Inc. and Johnson & Johnson	<p>Lines, J.L. <i>et al. Cancer Res.</i>; published online April 1, 2014; doi:10.1158/0008-5472.CAN-13-1504 Contact: J. Louise Lines, King's College London, London, U.K. e-mail: janet.lines@kcl.ac.uk</p> <p>Le Mercier, I. <i>et al. Cancer Res.</i>; published online April 1, 2014; doi:10.1158/0008-5472.CAN-13-1506 Contact: Li Wang, Geisel School of Medicine at Dartmouth, Lebanon, N.H. e-mail: li.wang@dartmouth.edu</p>
		<p>SciBX 7(18); doi:10.1038/scibx.2014.521 Published online May 8, 2014</p>		